NKGen Biotech (NKGN) has released an update.
NKGen Biotech, Inc. has amended its forward purchase agreement with Meteora Capital entities to increase the Prepayment Shortfall by $200,000 and boost the Share Consideration by 200,000 shares of common stock. This fourth amendment reflects a continuing evolution of the company’s financial strategies without altering the remaining terms of the agreement.
For further insights into NKGN stock, check out TipRanks’ Stock Analysis page.
